ATS Assemblies & Sections podcast

Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis

0:00
26:49
Recuar 15 segundos
Avançar 15 segundos

April 21, 2026

A Podcast on Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis.

A portion of the ATS SRN 360 high impact articles from the past year.
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity – Presented by Richard J Schwab, MD - Perelman School of Medicine, University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

Presented by Scott A. Sands, Ph.D - Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts

Moderated by Chana Chin, MD from CHOC Children's/Rady's Children's Health and Bradon Nokes, MD from University of California, San Diego

00:00 — Podcast Introduction & Presentation Overview 

00:15 — Tirzepatide for Obstructive Sleep Apnea and Obesity 

00:47 — SURMOUNT-OSA Trial Design and Patient Population 

01:44 — Primary Endpoints and Secondary Outcome Measures 

02:53 — Baseline Demographics and Clinical Characteristics 

03:52 — Weight Loss Effects and Sleep Apnea Improvement Results 

05:52 — Cardiometabolic Outcomes, Blood Pressure, and Safety Findings 

08:40 — Clinical Discussion: Prescribing Tirzepatide in OSA Practice 

12:03 — Secondary Analysis of Cardiometabolic Risk Mediation 

20:08 — Long-Term Use, Mechanisms of Action, and Audience Q&A

Mais episódios de "ATS Assemblies & Sections"